MiMedx Group, Inc
NNASDAQ:MDXGCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph H. Capper
- Full Time Employees
- 808
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1775 West Oak Commons Court, NE Marietta GA United States 30062
- IPO Date
- Aug 20, 2007
- CIK
- 0001376339
- Website
- mimedx.com
- Similar Companies
- Business
- MiMedx Group, Inc. is a biopharmaceutical enterprise dedicated to developing and commercializing regenerative biomaterial products and bioimplants derived from human placental tissues. The company employs its patented and proprietary PURION process to prepare these allografts, ensuring the retention of the tissue’s inherent biological properties, including crucial regulatory proteins. This distinctive processing method incorporates aseptic techniques alongside terminal sterilization to deliver robust solutions. Its portfolio encompasses a variety of advanced tissue-based products. EpiFix, a flagship offering, is a dehydrated human amnion/chorion membrane allograft designed as a protective barrier for persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. AmnioFix, also a dehydrated human amnion/chorion membrane allograft, serves in surgical recovery, including applications in orthopedics, spine, and sports medicine. A micronized injectable form of AmnioFix, known as mdHACM, is currently under clinical investigation for conditions like knee osteoarthritis, having received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. EpiCord, a dehydrated human umbilical cord allograft, leverages hyaluronic acid and collagen to foster a healing environment in advanced wound care and surgical settings. Recent additions include EPIEFFECT, a lyophilized placental-based allograft introduced in September 2023 for acute and chronic wounds, and EPIXPRESS, a next-generation lyophilized placental allograft launched in October 2025 that features fenestrations for enhanced fluid movement. The company's products primarily address needs in advanced wound care, burn treatment, and surgical recovery. Additionally, MiMedx supplies allografts for ophthalmic and dental applications through various partnerships. The distribution model relies on a direct sales force, independent sales agents, and distributors, predominantly within the United States, including federal healthcare agencies. Recent strategic initiatives include a July 2025 collaboration with Vaporox, Inc. to co-promote wound care offerings, coupled with a strategic investment. Headquartered in Marietta, Georgia, MiMedx Group, Inc. reported record quarterly revenue of $114 million in Q3 2025 and full-year 2024 revenue of $349 million.
Company News
MIMEDX to Participate in Upcoming Investor Conferences
What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
MIMEDX Announces $25 Million Patent License Agreement
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from Analysts
Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MIMEDX to Participate in Upcoming Investor Conferences
Deutsche Bank AG Takes $520,000 Position in MiMedx Group, Inc $MDXG
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
MiMedx Group Q2 Earnings Call Highlights
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MIMEDX to Acquire Sanara MedTech
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29